OR WAIT 15 SECS
The company invested in a new cGMP facility located in Berlin, Germany.
SGS announced on Oct. 3, 2016 that it will invest in a new cGMP facility in Berlin, Germany to expand its activities in R&D and quality control testing, and to offer new analytical services. The laboratories are due to open mid-2017, and will replace the current 2500 m2 facility in the city that was opened in 1985.
Construction on the new facility has been triggered by increased demand for stability testing, the handling of cytotoxic substances for oncology drug products, elemental impurity testing according to USP <232>, USP <233>, and ICH Q3D (Step 4); particle testing; and container testing according to USP and Ph.Eur, SGS said in a statement. “The new facility also gives the opportunity to expand in important growth areas like oncology drug products and stability studies,” Sheida Hoenlinger, director, Life Sciences Germany said in a statement.
This investment follows the recent announcement by SGS that it has opened a new facility in Wiesbaden, Germany as a dedicated Global Center of Excellence for the testing of extractables and leachables within pharmaceutical products.